Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of trends in the availability of pancreatic cancer drugs.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is aware of ongoing intermittent supply issues with pancreatic enzyme replacement therapy (PERT) used in the treatment of pancreatic cancer. We have been continuously assessing the availability of all PERT presentations for the duration of the supply disruption and implementing mitigation measures where there are any supply gaps. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. Through these discussions we have managed to secure additional volumes for 2025 for the United Kingdom, and we are in regular communication with suppliers on expected volumes for 2026.
The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. We have widely disseminated comprehensive guidance to healthcare professionals, including National Health Service trusts, general practices, and pharmacies, about these supply issues, which provide advice on how to manage patients whilst there is disruption to supply. The Department will continue to work closely with the manufacturers to resolve the issues as soon as possible, to ensure patients have continuous access to medicines.
The Department is also aware of a supply issue with mitomycin 10 milligram and 40 milligram powder for solution injection vials, a type of chemotherapy which may be used in the treatment of pancreatic cancer, which are out of stock until mid-January 2026. Alternative treatments have been sourced, and guidance has been issued to health care professionals with management advice until this issue is resolved.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure the consistent implementation of (a) Non-Specific Symptom pathways, (b) GP direct access and (c) NHS England Best Practice Timed Pathways to ensure (i) faster and (ii) earlier diagnosis of people with pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England has completed the national roll-out of non-specific symptom (NSS) pathways to support faster diagnosis of cancer in patients who present with symptoms that do not align with a single cancer site.
We are investing an additional £1.1 billion in general practices (GPs), bringing total GP Contract spend to £13.4 billion in 2025/26, the biggest increase in over a decade. NHS England has also expanded GP direct access to diagnostic tests, enabling faster investigation of concerning symptoms.
The National Health Service has also launched a new £2 million programme which is funding 300 GPs to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss for urgent testing.
NHS England continues to implement Best Practice Timed Pathways to ensure consistent and faster diagnosis in line with the Faster Diagnosis Standard. Alongside this, it is working with Pancreatic Cancer UK on a Family History Checker to help individuals assess inherited risk, and has launched the National Inherited Cancer Predisposition Register, which supports earlier identification and screening of high-risk individuals.
Asked by: Tanmanjeet Singh Dhesi (Labour - Slough)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of a national multi-cancer case finding programme to identify individuals at high risk of (a) pancreatic cancer and (b) all other cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
NHS England is developing case-finding approaches for less survivable cancers where the evidence supports this, including pancreatic cancer.
This work includes the development of a public-facing Family History Checker in partnership with Pancreatic Cancer UK, which enables individuals and families affected by pancreatic cancer to assess inherited risk. Those identified as being at risk are referred directly to the European Registry of Hereditary Pancreatic Diseases research trial. Referrals can be made by any healthcare professional or by individuals via self-referral, contributing to a more consistent and centralised approach to case-finding.
The National Disease Registration Service has launched the National Inherited Cancer Predisposition Register, which identifies individuals at increased inherited risk of a wide range of cancers, including pancreatic cancer. The register supports targeted screening and surveillance and will act as an electronic referral route into national screening programmes where these exist.
Asked by: Bambos Charalambous (Labour - Southgate and Wood Green)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to increase research funding into new (a) tools and (b) other technologies for the earlier diagnosis of (i) pancreatic, (ii) lung, (iii) liver, (iv) stomach, (v) brain, (vi) oesophageal cancers and (vii) other the less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR).
An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.
The NIHR is also funding a new artificial intelligence (AI) powered radiology analysis service, designed to develop and evaluate the use of AI in medical imaging to improve the detection of cancers, including for lung and brain tumours. The use of this technology will help to speed up response times and provide more accurate diagnoses and better-targeted treatments, ultimately improving outcomes for patients.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Danny Beales (Labour - Uxbridge and South Ruislip)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of minimally invasive therapies for the less survivable cancers.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Ongoing research is exploring the potential of minimally invasive cancer therapies for less survivable cancers. This includes non-invasive liver cancer treatments that use ultrasound technology to destroy tumours without surgery, scalpels, or radiation, with minimal damage to surrounding organs.
The adoption of new treatments, including minimally invasive cancer treatments for less survivable cancers, into the National Health Service in England is generally the result of National Institution of Clinical Excellence (NICE) guidance and/or commissioner decisions.
The NHS has launched a new £2 million programme which is funding 300 general practices to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss for urgent testing.
Both NHS England and the integrated care boards are required to put in place access for any treatment that carries a positive recommendation from the Technology Appraisal programme, operated by NICE. Agreements on timelines and funding for making therapies available on the NHS can vary, with implementation supported by the service readiness assessment and the development of additional capacity where necessary.
Asked by: Abtisam Mohamed (Labour - Sheffield Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking with (a) UK Research and Innovation and (b) the National Institute for Health and Care Research to prioritise further research into early diagnosis of (i) pancreatic cancer and (ii) other less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department of Health and Social Care invests over £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Government responsibility for funding cancer research is shared between UK Research and Innovation, funded by the Department for Science, Innovation and Technology and including the Medical Research Council, and the NIHR. Research funders work closely to drive the maximum collective research impact on policy, practice, and individual lives.
NIHR investments are pivotal to informing efforts to improve cancer prevention, treatment, and outcomes. An example of this is the NIHR investing £2.4 million into the miONCO-Dx trial, which seeks to develop a blood test designed to detect 12 different cancers, that could transform how cancer is diagnosed in the National Health Service.
The NIHR continues to welcome funding applications for research into any aspect of human health and care, including all cancers. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality. Welcoming applications on all cancers to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.
The forthcoming National Cancer Plan will include further details on how the NHS will improve diagnosis and outcomes for cancer patients in England.
Asked by: Helen Maguire (Liberal Democrat - Epsom and Ewell)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether the forthcoming national cancer plan will include specific (a) targets and (b) actions for (i) brain, (ii) liver, (iii) lung, (iv) oesophageal, (v) pancreatic and (vi) stomach cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Reducing the number of lives lost to cancer is a key aim of the National Cancer Plan. Having consulted with key stakeholders and patient groups, I confirm that the plan will be published early in the new year. The plan will include further details on how we will improve outcomes for patients with cancer, including less survivable cancers, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.
The Department has been working with members of the Less Survivable Cancers Taskforce as part of the development of the plan to identify how to improve diagnosis, treatment, and outcomes for less survivable cancers, which includes lung, pancreatic, liver, brain, oesophageal, and stomach cancer.
Asked by: Allison Gardner (Labour - Stoke-on-Trent South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what factors are considered when allocating investment for research in the less survivable cancers; and what steps he is taking to combat underfunding for less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Cancer is one of the largest areas of spend at over £133 million in 2023/24, reflecting its high priority.
These investments are pivotal to informing our efforts to improve cancer prevention, treatment, and outcomes. An example of this investment is Imperial College London’s research on breath tests to detect less survivable cancers, including pancreatic cancer. Further information on the research is available at the following link:
https://imperialbrc.nihr.ac.uk/2023/06/05/imperial-led-uk-cancer-breath-tests-reach-final-stages/
Another example of Government investment was the launch of the NIHR’s national Brain Tumour Research Consortium in September 2024, which is bringing together researchers from a range of different disciplines and institutions with the aim of making scientific advances in how we prevent, detect, manage, and treat rare and less-survivable brain tumours in adults and children.
The NIHR welcomes further high-quality proposals from researchers to inform approaches to prevention, treatment, and care in relation to less survivable cancers. Furthermore, the Government is committed to ensuring that all patients have access to cutting-edge clinical trials and innovative, lifesaving treatments. The Government supports the Rare Cancers Bill and its ambitions to incentivise clinical trials and access to innovative treatments for rare cancers.
The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for less common cancers.
Asked by: Patrick Hurley (Labour - Southport)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage research into detection (a) tools and (b) tests for the early detection of (i) pancreatic and (ii) other less survivable cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Research is crucial in tackling cancer, which is why the Department invests £1.6 billion each year on research through its research delivery arm, the National Institute for Health and Care Research (NIHR). Cancer is one of the largest areas of spend at over £133 million in 2023/24, reflecting its high priority.
These investments are pivotal to informing our efforts to improve cancer prevention, treatment, and outcomes. An example of this investment is Imperial College London’s research on breath tests to detect less survivable cancers, including pancreatic cancer. Further information on the research is available at the following link:
https://imperialbrc.nihr.ac.uk/2023/06/05/imperial-led-uk-cancer-breath-tests-reach-final-stages/
Another example of Government investment was the launch of the NIHR’s national Brain Tumour Research Consortium in September 2024, which is bringing together researchers from a range of different disciplines and institutions with the aim of making scientific advances in how we prevent, detect, manage, and treat rare and less-survivable brain tumours in adults and children.
The NIHR welcomes further high-quality proposals from researchers to inform approaches to prevention, treatment, and care in relation to less survivable cancers. Furthermore, the Government is committed to ensuring that all patients have access to cutting-edge clinical trials and innovative, lifesaving treatments. The Government supports the Rare Cancers Bill and its ambitions to incentivise clinical trials and access to innovative treatments for rare cancers.
The forthcoming National Cancer Plan will include further details on how the National Health Service will improve diagnosis and outcomes for all cancer patients in England, including for less common cancers.
Asked by: Darren Paffey (Labour - Southampton Itchen)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Medicines and Healthcare products Regulatory Agency on the potential impact (a) emerging diagnostic technologies and (b) breath testing on (i) detection and (ii) survival rates for people for pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not had discussions with the Medicines and Healthcare products Regulatory Agency on this topic, however we remain committed to improving survival rates for people with all cancers including pancreatic cancer.
The National Cancer Plan for England will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates.